// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

14-3-3zeta Is Required for PKA-Dependent Lipolysis

ABEL OPPONG - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Isoproterenol

Gut Microbes after Bariatric Surgery in Humans Improve Glucose Control in Mice without Fat Loss

FERNANDO FORATO ANHa - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

The Role of 14-3-3zeta in the “Beigingâ€ of White Adipose Tissue

KADIDIA DIALLO - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

Isoproterenol

Gut Microbes Regulate Insulin Clearance in Mice

KEVIN P. FOLEY - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

Insulin human

The Protein-Tyrosine Phosphatase Shp1 Interacts with PPAR Gamma and Regulates Its Transcriptional Activity through Dephosphorylation of Selected Tyrosine Sites

AMIT KUMAR - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fatty Liver Disease

L-Tyrosine

Liver-Specific p38 MAPK Stimulates Hepatic Fat Accumulation and Reduces Insulin Sensitivity In Vivo

SYDNEY L. RIVERS - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

VLTS-934

Inflammatory Triggers of Lipolysis Act through IRE1 in Adipocytes

KEVIN P. FOLEY - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

ILS-969

Results from the Canadian Study of Longevity in Type 1 Diabetes

NANCY CARDINEZ - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

Pancreas Single-Cell Patch-Seq Links Physiologic Dysfunction in Diabetes to Transcriptomic Phenotypes

JOAN CAMUNAS SOLER - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

Reconcile

Comorbid Autoimmune Disease in Participants at Risk for Type 1 Diabetes

KIMBER SIMMONS - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

Data from the Canadian LMC Diabetes Registry

RONNIE ARONSON - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diabetic retinopathy

Analogue insulin

A Validation Study

ALANNA WEISMAN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

Metformin Hydrochloride

A Population-Based Study

GHAZAL FAZLI - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Prediabetes

N/A

Vagus Nerve Stimulation for Chronic Heart Failure: Differences in Therapy Delivery and Clinical Efficacy in ANTHEM-HF, INOVATE-HF, and NECTAR-HF

Inder S. Anand - Heart Failure Society of America (HFSA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Problem of 30-Day Readmission for Heart Failure Could Be Improved. Results of IMPEDANCE-HF Extended Trial

Michael Kleiner Shochat - Heart Failure Society of America (HFSA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary edema

N/A

Evaluation of Pain Reproduction and other Predictive Factors of Selective Lumbar Nerve Block Efficacy for the Diagnosis and Palliative Treatment of Chronic Low Back Pain: A Retrospective Cohort Study (P2.095)

Yi Tong - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

N/A

Overcoming Therapeutic Inertia in Multiple Sclerosis care: A pilot Randomized Trial evaluating an Educational Intervention (P4.394)

Gustavo Saposnik - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Anxiety and Diabetes Adversely Affect Cognition in Multiple Sclerosis (P1.423)

Ruth-Ann Marrie - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Neurons on Wheels (NOW) – Bringing Neurologists Into Shelters for Better Patient Care (P5.085)

Joy Ding - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Sensory-Motor Network Functional Connectivity in Hemiparetic Children With Perinatal Stroke (P3.297)

Kristine Woodward - American Academy of Neurology (AAN) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved